Ryan Veterinary Hospital at the University of Pennsylvania for evaluation of chronic bilateral ocular discharge and blepharospasm. Initial ophthalmic examination revealed severe conjunctivitis and keratitis and the presence

of upper eyelid distichiae bilaterally. Initial therapy for suspected feline herpesviral infection provided moderate, but not complete, CA3 resolution of the clinical signs. Over the subsequent year, the cat suffered from recurrent, severe, ulcerative keratitis in both eyes despite appropriate medical therapy. Approximately 13 months after the initial presentation, the distichiae were surgically removed using transconjunctival electrocautery, which resulted in complete resolution of the clinical signs. S3I-201 This report documents bilateral distichiasis in a cat, a condition that is considered rare in this species.”
“Montelukast is a leukotrien receptor antagonist used for asthma treatment. Objective of this study was to evaluate the bioequivalence of two montelukast 10mg tablets, Innovator drug (Singulair) as reference

and other locally manufactured drug (Montiget) in 12 healthy volunteers. It was randomized, single dose, two-period crossover study with 1 week washout period. Blood samples (4-5 ml) were collected before and after drug administration and plasma was separated for analysis. Concentrations of montelukast at different time intervals were determined by validated UV-HPLC method at 345nm wavelength. Bioequivalence was assessed by using non compartmental approach and also calculated the 90% confidence interval of the least-squared pharmacokinetic parameters (C-max, AUC(0-t) and AUC(0-infinity)). PDGFR inhibitor On average, C-max, AUC(0-t), AUC(0-inf), was 2.35 mu g/ml, 1.28 mu g.h./ml, 1.67 mu g.h./ml, for innovator drug and 2.53 mu g/ml, 1.53 mu g.h./ml, 1.96 mu g.h./ml, for test drug, respectively. Confidence interval (90%)

for C-max, AUC(0-t) and AUC(0-inf) was 89-97%, 85-91% and 81-98% respectively. No statistical difference was found between the C,a and AUC values of test and reference drugs. The confidence intervals for C-max, AUC(0-t) and AUC(0-infinity) are fully laid within the acceptable range of FDA (80-125%), finis two formulations are considered to be bioequivalent.”
“The use of pedicled buccal fat pad flap (BFP) has proved of value for the closure of oroantral and oronasal communications and is a well-established tool in oral and maxillofacial surgery. Otherwise, the perceived limitations of surgical therapy for bisphosphonate-related osteonecrosis of the jaws (BRONJ) have been widely discussed, and recommendations have largely been made to offer aggressive surgery only to stage 3 patients refractary to conservative management. Oroantral communication may be a common complication after sequestrectomy and bone debridement in upper maxillary BRONJ.